1 clinical trials involving this therapy/drug
This is not medical advice - consult your oncologist
Descriptions are automatically translated with AI assistance. Always verify details in the original on ClinicalTrials.gov and consult your treating physician.
The purpose of this phase I/II clinical trial is to test CARCIK-CD123/33 cells to treat patients with R/R AML/BPDCN, who have otherwise exhausted conventional treatment options. In particular, this study will assess the safety and feasibility of CARCIK-CD123/33 cells infusion in adults and children with R/R AML, ahead of scheduled alloHCT.
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.
We use Google Analytics to understand how you use our tools and to improve them. We don't collect health data and we don't show ads. You can decline - the site will work exactly the same. Privacy policy